HK1170244A1 - 包含馮維勒布蘭德因子 的製劑及其相關製備方法、試劑盒和用途 - Google Patents

包含馮維勒布蘭德因子 的製劑及其相關製備方法、試劑盒和用途

Info

Publication number
HK1170244A1
HK1170244A1 HK12110787.2A HK12110787A HK1170244A1 HK 1170244 A1 HK1170244 A1 HK 1170244A1 HK 12110787 A HK12110787 A HK 12110787A HK 1170244 A1 HK1170244 A1 HK 1170244A1
Authority
HK
Hong Kong
Prior art keywords
vwf
kits
methods
von willebrand
willebrand factor
Prior art date
Application number
HK12110787.2A
Other languages
English (en)
Inventor
Thomas Barnett
Original Assignee
Grifols Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics Inc filed Critical Grifols Therapeutics Inc
Publication of HK1170244A1 publication Critical patent/HK1170244A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12110787.2A 2009-11-13 2012-10-29 包含馮維勒布蘭德因子 的製劑及其相關製備方法、試劑盒和用途 HK1170244A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26114509P 2009-11-13 2009-11-13
PCT/US2010/056496 WO2011060242A2 (en) 2009-11-13 2010-11-12 Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto

Publications (1)

Publication Number Publication Date
HK1170244A1 true HK1170244A1 (zh) 2013-02-22

Family

ID=43992414

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110787.2A HK1170244A1 (zh) 2009-11-13 2012-10-29 包含馮維勒布蘭德因子 的製劑及其相關製備方法、試劑盒和用途

Country Status (20)

Country Link
US (1) US8759293B2 (zh)
EP (1) EP2499165B1 (zh)
JP (1) JP5876416B2 (zh)
KR (1) KR101808751B1 (zh)
CN (1) CN102648212B (zh)
AU (1) AU2010319425B2 (zh)
BR (1) BR112012011740A2 (zh)
CA (1) CA2780542C (zh)
CL (1) CL2012001258A1 (zh)
ES (1) ES2600879T3 (zh)
HK (1) HK1170244A1 (zh)
HU (1) HUE029454T2 (zh)
IL (1) IL219679A (zh)
MX (1) MX2012005527A (zh)
NZ (1) NZ600278A (zh)
PL (1) PL2499165T3 (zh)
PT (1) PT2499165T (zh)
RU (1) RU2579977C2 (zh)
WO (1) WO2011060242A2 (zh)
ZA (1) ZA201203795B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2499165B1 (en) 2009-11-13 2016-09-14 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
AU2012324020A1 (en) 2011-12-30 2013-07-18 Grifols, S.A. Method for purifying Factor VIII
LT2802668T (lt) 2012-01-12 2018-11-26 Bioverativ Therapeutics Inc. Imunogeninio atsako prieš faktorių viii individuose, kuriems skiriama faktoriaus viii terapija, sumažinimas
LT2804623T (lt) * 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
BR112015009229B1 (pt) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
GB201304973D0 (en) * 2013-03-19 2013-05-01 Profactor Pharma Ltd Recombinant protein
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
WO2014198699A2 (en) * 2013-06-12 2014-12-18 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
US20160229903A1 (en) * 2013-06-28 2016-08-11 Biogen Ma Inc. Thrombin cleavable linker
EP4368194A3 (en) * 2013-06-28 2024-07-31 Bioverativ Therapeutics Inc. Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (en) * 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) * 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
US9701933B2 (en) * 2014-09-19 2017-07-11 Sarfaraz K. Niazi Harvesting and purification or perfusion yielder (HAPPY) device
CN107406493B (zh) * 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
AU2016266627A1 (en) 2015-05-22 2018-01-18 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
CN108779165B (zh) 2016-01-07 2022-12-02 康诺贝林伦瑙有限公司 突变的冯·维勒布兰德因子
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
DK3538133T3 (da) * 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
EP3538134B1 (en) 2016-11-11 2021-12-29 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
EP3612209A4 (en) 2017-04-20 2021-03-24 The University of Chicago METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER WITH ECM AFFINITY PEPTIDES BONDED TO IMMUNOTHERAPEUTIC ANTIBODIES
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides
CA3068098A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
RU2766118C2 (ru) * 2017-07-07 2022-02-08 Такеда Фармасьютикал Компани Лимитед Лечение пациентов с тяжелой формой болезни фон виллебранда, подвергающихся плановому хирургическому вмешательству, путем введения рекомбинантного ффв
CA3081106A1 (en) * 2017-11-01 2019-05-09 Queen's University At Kingston Von willebrand factor proteins for treating bleeding disorders
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
US10654911B1 (en) 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2024106355A1 (ja) * 2022-11-14 2024-05-23 セルジェンテック株式会社 血液凝固第ｖｉｉｉ因子改変体を産生するエクスビボ遺伝子治療用細胞

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234991A (en) 1975-07-29 1993-08-10 Pasteur Merieux Serums And Vaccines Porous mineral support coated with an aminated polysaccharide polymer
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
FR2616437B1 (fr) 1987-06-11 1990-09-07 Ibf Polymeres composites, leur preparation et leur utilisation en chromatographie liquide
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5683912A (en) 1994-07-21 1997-11-04 The Salk Institute For Biological Studies Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
MX9203011A (es) * 1991-06-20 1993-08-01 Rhone Poulenc Rorer Int Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
DK0669929T3 (da) 1992-11-13 2007-01-29 Immunex Corp Elk-ligand, et cytokin
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
DE69701671T3 (de) 1996-01-23 2006-08-17 Qiagen Genomics, Inc., Bothell Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekülen
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
WO1998003683A1 (en) 1996-07-19 1998-01-29 The Regents Of The University Of Michigan Dna encoding canine von willebrand factor and methods of use
US6074832A (en) 1996-07-19 2000-06-13 The Regents Of The University Of Michigan DNA encoding canine von Willebrand factor and methods of use
US6063593A (en) 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6489290B2 (en) 1997-03-27 2002-12-03 Trustees Of Boston University Antiplatelet agent
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
EP1000176A1 (en) 1997-07-22 2000-05-17 Rapigene, Inc. Computer method and system for correlating sequencing data by ms
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US7144996B1 (en) 1999-03-05 2006-12-05 Genentech, Inc. Nucleic acid encoding human suppressor of fused
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
JP2004509609A (ja) 2000-06-02 2004-04-02 ブルー　ヘロン　バイオテクノロジー　インコーポレイテッド 合成二本鎖オリゴヌクレオチドの配列忠実度を改善するための方法
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
AU2001277217A1 (en) 2000-07-28 2002-02-13 Blood Center Research Foundation Synthetic and recombinant substrates for the detection of the von willebrand factor-cleaving protease
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
EP1438401B1 (en) 2001-09-18 2011-06-15 Synageva BioPharma Corp. Production of a transgenic avian by cytoplasmic injection
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
EP1456235A4 (en) 2001-11-30 2005-08-17 Univ Emory VARIANTS OF DOMAIN C2 OF FACTOR VIII
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
PT1543106E (pt) 2002-07-15 2007-05-31 Immunex Corp Métodos e meios para controlar a sialilação de proteínas produzidas por células de mamíferos
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
ES2333598T5 (es) * 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP2005073528A (ja) * 2003-08-28 2005-03-24 Genetics Inst Llc 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ES2593318T3 (es) 2004-08-12 2016-12-07 Lipoxen Technologies Limited Derivados de ácido siálico
US20070066551A1 (en) 2004-09-07 2007-03-22 Keefe Anthony D Aptamer medicinal chemistry
GB0423974D0 (en) 2004-10-28 2004-12-01 Ares Trading Sa Proteins
US7884075B2 (en) * 2004-12-27 2011-02-08 Baxter International Inc. Polymer-factor VIII-von Willebrand factor-conjugates
CA2593328C (en) 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US9012605B2 (en) * 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR20090031897A (ko) 2006-06-12 2009-03-30 리셉터 바이오로직스 인크 전-세포 표면 수용체-특이적 치료제
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
NZ585530A (en) 2007-12-27 2012-06-29 Baxter Int Methods for differentiating plasma-derived protein from recombinant protein in a sample
EP3936116A1 (en) 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations
KR101507718B1 (ko) * 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
US20110086362A1 (en) 2009-10-09 2011-04-14 Massachusetts Institute Of Technology High-Throughput Method for Quantifying Sialylation of Glycoproteins
EP2499165B1 (en) 2009-11-13 2016-09-14 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto

Also Published As

Publication number Publication date
EP2499165A4 (en) 2013-09-11
ES2600879T3 (es) 2017-02-13
AU2010319425A1 (en) 2012-06-14
ZA201203795B (en) 2014-10-29
WO2011060242A2 (en) 2011-05-19
US8759293B2 (en) 2014-06-24
KR101808751B1 (ko) 2017-12-13
CN102648212A (zh) 2012-08-22
CA2780542C (en) 2020-03-24
IL219679A (en) 2016-11-30
AU2010319425B2 (en) 2015-07-02
MX2012005527A (es) 2012-08-08
JP2013510581A (ja) 2013-03-28
CN102648212B (zh) 2014-12-03
KR20120113214A (ko) 2012-10-12
IL219679A0 (en) 2012-07-31
PT2499165T (pt) 2016-10-28
HUE029454T2 (en) 2017-03-28
BR112012011740A2 (pt) 2018-03-27
NZ600278A (en) 2014-04-30
EP2499165B1 (en) 2016-09-14
RU2579977C2 (ru) 2016-04-10
JP5876416B2 (ja) 2016-03-02
RU2012122402A (ru) 2013-12-20
EP2499165A2 (en) 2012-09-19
WO2011060242A3 (en) 2011-10-13
CL2012001258A1 (es) 2012-09-14
PL2499165T3 (pl) 2017-04-28
US20120289468A1 (en) 2012-11-15
CA2780542A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
HK1170244A1 (zh) 包含馮維勒布蘭德因子 的製劑及其相關製備方法、試劑盒和用途
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
HK1211228A1 (zh) 具有 和血管性血友病因子蛋白的因子 複合物、及其用途
IL233934A0 (en) Antibodies to cd47, preparations containing them and their uses
EP2627358C0 (en) PRETARGETING KIT, METHOD AND MEANS USED THEREIN
AP2010005332A0 (en) Humanized antibodies specific for von willebrand factor.
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
IL226383B (en) Antibodies against ccl20, preparations containing them and their uses
IL225460B (en) Antibodies that bind to p4d12191, preparations containing them and their uses
GB201109198D0 (en) Gesture based edit mode
GB2497478B (en) Substrate with built-in component, and method the same
HK1183514A1 (zh) 免疫層析裝置、方法和試劑盒
SG10201709806VA (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
PT2078730E (pt) Processo para a obtenção de um concentrado do factor de von willebrand ou de um complexo factor viii/factor de von willebrand e sua utilização
EP2618326A4 (en) PORTABLE TERMINAL, ITS CONTROL METHOD AND PROGRAM
ZA201406381B (en) Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof
WO2012050963A3 (en) Agents providing controls and standards for immuno-precipitation assays
EP2193373A4 (en) METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR
EP2238146A4 (en) HEMAGGLUTININ POLYPEPTIDES, REAGENTS, AND METHODS RELATING THERETO
GB201119716D0 (en) Post and panel assembly and method, e.g. for glazed parapet
GB0523529D0 (en) Von willebrand factor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201110